357 related articles for article (PubMed ID: 15225110)
21. Medical therapy for intermittent claudication.
Rowlands TE; Donnelly R
Eur J Vasc Endovasc Surg; 2007 Sep; 34(3):314-21. PubMed ID: 17532651
[TBL] [Abstract][Full Text] [Related]
22. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Ishiwata N; Noguchi K; Kawanishi M; Asakura Y; Hori M; Mitani A; Ito Y; Takahashi K; Nishiyama H; Shudo N; Takahashi S; Takahashi K; Tsuruzoe N; Nakaike S
Life Sci; 2007 Sep; 81(12):970-8. PubMed ID: 17850826
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK.
Guest JF; Davie AM; Clegg JP
Curr Med Res Opin; 2005 Jun; 21(6):817-26. PubMed ID: 15969881
[TBL] [Abstract][Full Text] [Related]
24. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
Dawson DL; Cutler BS; Meissner MH; Strandness DE
Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
[TBL] [Abstract][Full Text] [Related]
25. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication.
Lee C; Nelson PR
Vasc Endovascular Surg; 2014 Apr; 48(3):224-9. PubMed ID: 24399131
[TBL] [Abstract][Full Text] [Related]
26. Cilostazol for peripheral arterial disease.
Robless P; Mikhailidis DP; Stansby GP
Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
[TBL] [Abstract][Full Text] [Related]
27. The US experience with cilostazol in treating intermittent claudication.
Hiatt WR
Atheroscler Suppl; 2005 Dec; 6(4):21-31. PubMed ID: 16275166
[TBL] [Abstract][Full Text] [Related]
28. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
Stone WM; Demaerschalk BM; Fowl RJ; Money SR
J Stroke Cerebrovasc Dis; 2008; 17(3):129-33. PubMed ID: 18436153
[TBL] [Abstract][Full Text] [Related]
29. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication.
Delaney CL; Spark JI; Thomas J; Wong YT; Chan LT; Miller MD
Atherosclerosis; 2013 Jul; 229(1):1-9. PubMed ID: 23557982
[TBL] [Abstract][Full Text] [Related]
30. The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial.
Hobbs SD; Marshall T; Fegan C; Adam DJ; Bradbury AW
J Vasc Surg; 2007 Jan; 45(1):65-70; discussion 70. PubMed ID: 17210383
[TBL] [Abstract][Full Text] [Related]
31. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
[TBL] [Abstract][Full Text] [Related]
32. Rapid foot and calf compression increases walking distance in patients with intermittent claudication: results of a randomized study.
Ramaswami G; D'Ayala M; Hollier LH; Deutsch R; McElhinney AJ
J Vasc Surg; 2005 May; 41(5):794-801. PubMed ID: 15886663
[TBL] [Abstract][Full Text] [Related]
33. Cilostazol for peripheral arterial disease.
Robless P; Mikhailidis DP; Stansby GP
Cochrane Database Syst Rev; 2008 Jan; (1):CD003748. PubMed ID: 18254032
[TBL] [Abstract][Full Text] [Related]
34. Cilostazol.
Cheng JW
Heart Dis; 1999; 1(3):182-6. PubMed ID: 11720622
[TBL] [Abstract][Full Text] [Related]
35. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
Hood SC; Moher D; Barber GG
CMAJ; 1996 Oct; 155(8):1053-9. PubMed ID: 8873633
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of cilostazol in the management of intermittent claudication.
Chi YW; Lavie CJ; Milani RV; White CJ
Vasc Health Risk Manag; 2008; 4(6):1197-203. PubMed ID: 19337533
[TBL] [Abstract][Full Text] [Related]
37. Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication.
de Albuquerque RM; Virgini-Magalhães CE; Lencastre Sicuro F; Bottino DA; Bouskela E
Angiology; 2008; 59(5):549-58. PubMed ID: 18388031
[TBL] [Abstract][Full Text] [Related]
38. From the Cochrane library: Ginkgo biloba for intermittent claudication.
Nicolaï SP; Gerardu VC; Kruidenier LM; Prins MH; Teijink JA
Vasa; 2010 May; 39(2):153-8. PubMed ID: 20464671
[TBL] [Abstract][Full Text] [Related]
39. A meta-analysis of the outcome of endovascular and noninvasive therapies in the treatment of intermittent claudication.
Ahimastos AA; Pappas EP; Buttner PG; Walker PJ; Kingwell BA; Golledge J
J Vasc Surg; 2011 Nov; 54(5):1511-21. PubMed ID: 21958561
[TBL] [Abstract][Full Text] [Related]
40. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
Farkas K; Járai Z; Kolossváry E
Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
